Oncternal Therapeutics, Inc. (ONCT)
Dec 3, 2024 - ONCT trading suspended
0.5266
-0.1670 (-24.12%)
Inactive · Last trade price on Dec 2, 2024
Oncternal Therapeutics Stock Forecast
ONCT's stock price has decreased by -92.3% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Oncternal Therapeutics stock had an average target of $10, with a low estimate of $2.00 and a high estimate of $18.
Price Target: $10 (+1,798.97%)
Analyst Consensus: Buy
No price target forecast data available
Analyst Ratings
The average analyst rating for Oncternal Therapeutics stock from 3 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
No data available
| Rating | Oct 2026 |
|---|---|
| Strong Buy | n/a |
| Buy | n/a |
| Hold | n/a |
| Sell | n/a |
| Strong Sell | n/a |
| Total | n/a |
Financial Forecast
Revenue This Year
1.68M
from 785.00K
Increased by 113.76%
Revenue Next Year
612.00K
from 1.68M
Decreased by -63.53%
EPS This Year
-12.12
from -13.43
EPS Next Year
-10.46
from -12.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.0M | 630,000 | |
| Avg | 1.7M | 612,000 | |
| Low | 1.3M | 588,000 |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 156.8% | -62.5% | |
| Avg | 113.8% | -63.5% | |
| Low | 71.1% | -65.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -11.91 | -10.76 | |
| Avg | -12.12 | -10.46 | |
| Low | -12.18 | -10.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |